Lion Point Capital, LP
13F Reported Value
ⓘ$20.9M
Holdings
35
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Lion Point Capital, LP disclosed 35 positions worth $20.9M in its Form 13F-HR for Q2 2026, led by $CUE (Cue Biopharma, Inc.) at 8.0% of the equity portfolio, followed by $PRAX and $MLTX. The portfolio is most concentrated in Healthcare (98.8% of disclosed assets). All figures are sourced directly from Lion Point Capital, LP’s Form 13F-HR filing with the SEC under CIK 1643354.
AI Fund Analysis
StableSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 28.9#2,543
Quality
$1.7M52,928 sh - $1.5M4,450 sh
- —
Quality
$1.3M67,500 sh - 35.7
Quality
$1.2M112,434 sh - —
Quality
$1.2M21,400 sh - —
Quality
$1.1M80,000 sh - —
Quality
$1.1M820,000 sh - —
Quality
$829.6K62,000 sh - 33.8
Quality
$787.0K36,000 sh - —
Quality
$769.3K51,700 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Cue Biopharma, Inc.$CUE | 28.9#2,543 | $1.7M | 52,928 |
 Praxis Precision Medicines, Inc.$PRAX | — | $1.5M | 4,450 |
 MoonLake Immunotherapeutics$MLTX | — | $1.3M | 67,500 |
 FENNEC PHARMACEUTICALS INC.$FENC | 35.7 | $1.2M | 112,434 |
 Royalty Pharma plc$RPRX | — | $1.2M | 21,400 |
 COMPASS Pathways plc$CMPS | — | $1.1M | 80,000 |
 Milestone Pharmaceuticals Inc.$MIST | — | $1.1M | 820,000 |
 Benitec Biopharma Inc.$BNTC | — | $829.6K | 62,000 |
 Syndax Pharmaceuticals Inc$SNDX | 33.8 | $787.0K | 36,000 |
 Biohaven Ltd.$BHVN | — | $769.3K | 51,700 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Lion Point Capital, LP's 35 positions.
Showing top 10 of 35 holdings.
Sector Allocation
Healthcare
$20.7M
Industrials
$247,544
Full Holdings — Lion Point Capital, LP (Q2 2026)
All 35 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $CUE | Cue Biopharma, Inc. | $1.7M | 8.0% | -98% | 28.9 |
| 2 | $PRAX | Praxis Precision Medicines, Inc. | $1.5M | 7.1% | +0% | — |
| 3 | $MLTX | MoonLake Immunotherapeutics | $1.3M | 6.3% | +0% | — |
| 4 | $FENC | FENNEC PHARMACEUTICALS INC. | $1.2M | 5.8% | +0% | 35.7 |
| 5 | $RPRX | Royalty Pharma plc | $1.2M | 5.7% | +0% | — |
| 6 | $CMPS | COMPASS Pathways plc | $1.1M | 5.4% | +0% | — |
| 7 | $MIST | Milestone Pharmaceuticals Inc. | $1.1M | 5.3% | +0% | — |
| 8 | $BNTC | Benitec Biopharma Inc. | $829,560 | 4.0% | +0% | — |
| 9 | $SNDX | Syndax Pharmaceuticals Inc | $786,960 | 3.8% | +0% | 33.8 |
| 10 | $BHVN | Biohaven Ltd. | $769,296 | 3.7% | +0% | — |
| 11 |  $GERN | GERON CORP | $739,840 | 3.5% | +0% | — |
| 12 |  $QURE | uniQure N.V. | $677,082 | 3.2% | +0% | — |
| 13 |  $ARDX | ARDELYX, INC. | $656,115 | 3.1% | +0% | 41.9 |
| 14 |  $LNTH | Lantheus Holdings, Inc. | $610,170 | 2.9% | +0% | 61.1 |
| 15 |  $IRON | Disc Medicine, Inc. | $592,434 | 2.8% | +0% | — |
| 16 |  $SRPT | Sarepta Therapeutics, Inc. | $512,145 | 2.5% | +0% | 47.3 |
| 17 |  $HUMA | Humacyte, Inc. | $507,260 | 2.4% | +0% | 9.1 |
| 18 |  $KURA | Kura Oncology, Inc. | $504,620 | 2.4% | +0% | 27.6 |
| 19 |  $VTRS | Viatris Inc | $439,876 | 2.1% | +0% | 45.4 |
| 20 |  $DYN | Dyne Therapeutics, Inc. | $399,780 | 1.9% | +0% | — |
| 21 |  $BBIO | BridgeBio Pharma, Inc. | $372,400 | 1.8% | +0% | 36.9 |
| 22 |  $EWTX | Edgewise Therapeutics, Inc. | $369,733 | 1.8% | +0% | — |
| 23 |  $PCRX | Pacira BioSciences, Inc. | $342,495 | 1.6% | +0% | 51.5 |
| 24 |  $RGNX | REGENXBIO Inc. | $318,668 | 1.5% | +0% | 26.4 |
| 25 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $294,120 | 1.4% | +0% | — |
| 26 |  $JANX | Janux Therapeutics, Inc. | $291,840 | 1.4% | +0% | 30.1 |
| 27 |  $MLYS | Mineralys Therapeutics, Inc. | $283,290 | 1.4% | +0% | — |
| 28 |  $GHRS | GH Research PLC | $274,176 | 1.3% | +0% | — |
| 29 |  $MCRB | Seres Therapeutics, Inc. | $249,087 | 1.2% | +0% | 8.8 |
| 30 |  $AZTA | Azenta, Inc. | $247,544 | 1.2% | +0% | 28.2 |
| 31 |  $JSPR | Jasper Therapeutics, Inc. | $195,765 | 0.9% | +0% | — |
| 32 |  $INVA | Innoviva, Inc. | $186,222 | 0.9% | +0% | 71.4 |
| 33 |  $IPHA | Innate Pharma SA | $149,318 | 0.7% | +0% | — |
| 34 |  $ARQT | Arcutis Biotherapeutics, Inc. | $137,655 | 0.7% | +0% | 62.9 |
| 35 |  $SPRB | SPRUCE BIOSCIENCES, INC. | $54,000 | 0.3% | +0% | — |
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Lion Point Capital, LP including:
Track Lion Point Capital, LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Lion Point Capital, LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Lion Point Capital, LP
13F Pro is an AI hedge fund tracker and stock research platform. For Lion Point Capital, LP (SEC CIK: 1643354), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Lion Point Capital, LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.